Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
BMC Complement Altern Med. 2010 Feb 25;10:8. doi: 10.1186/1472-6882-10-8.
Natural health products (NHPs), such as herbal medicines and vitamins, are widely available over-the-counter and are often purchased by consumers without advice from a healthcare provider. This study examined how consumers respond when they believe they have experienced NHP-related adverse drug reactions (ADRs) in order to determine how to improve current safety monitoring strategies.
Qualitative semi-structured interviews were conducted with twelve consumers who had experienced a self-identified NHP-related ADR. Key emergent themes were identified and coded using content analysis techniques.
Consumers were generally not comfortable enough with their conventional health care providers to discuss their NHP-related ADRs. Consumers reported being more comfortable discussing NHP-related ADRs with personnel from health food stores, friends or family with whom they had developed trusted relationships. No one reported their suspected ADR to Health Canada and most did not know this was possible.
Consumers generally did not report their suspected NHP-related ADRs to healthcare providers or to Health Canada. Passive reporting systems for collecting information on NHP-related ADRs cannot be effective if consumers who experience NHP-related ADRs do not report their experiences. Healthcare providers, health food store personnel, manufacturers and other stakeholders also need to take responsibility for reporting ADRs in order to improve current pharmacovigilance of NHPs.
天然保健品(NHPs),如草药和维生素,在柜台上广泛销售,消费者经常在没有医疗保健提供者建议的情况下购买。本研究考察了消费者在认为自己经历了与 NHP 相关的药物不良反应(ADR)时的反应,以确定如何改进当前的安全监测策略。
对 12 名自认为经历过与 NHP 相关的 ADR 的消费者进行了定性半结构式访谈。使用内容分析技术识别和编码主要出现的主题。
消费者通常对他们的常规医疗保健提供者不够放心,无法讨论他们与 NHP 相关的 ADR。消费者报告说,他们更愿意与保健食品店的人员、与他们建立了信任关系的朋友或家人讨论与 NHP 相关的 ADR。没有人向加拿大卫生部报告他们怀疑的 ADR,而且大多数人不知道这是可能的。
消费者通常不会向医疗保健提供者或加拿大卫生部报告他们怀疑与 NHP 相关的 ADR。如果经历 NHP 相关 ADR 的消费者不报告他们的经历,收集 NHP 相关 ADR 信息的被动报告系统就无法有效。医疗保健提供者、保健食品店人员、制造商和其他利益相关者也需要对报告 ADR 负责,以改善对 NHPs 的当前药物警戒。